Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. (2nd November 2021)

• Record Type: Journal Article
• Authors: van Ingen, Jakko; Obradovic, Marko; Hassan, Mariam; Lesher, Beth; Hart, Erin; Chatterjee, Anjan; Daley, Charles L.
• Is Part Of: Expert review of respiratory medicine. Volume 15:Number 11(2021)
• Page Start: 1387
• Page End: 1401
• Publication Date: 2021-11-02
• Subjects: amikacin liposome inhalation suspension -- epidemiology -- lung disease -- mortality -- Mycobacterium avium complex -- nontuberculous mycobacterial lung disease -- NTM-LD; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2021.1987891
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction: Nontuberculous mycobacterial (NTM) lung disease (LD) is the most common clinical manifestation of NTM infection and is a growing health concern. Up to 85% of NTM-LD cases are caused by Mycobacterium avium complex (MAC). Increased awareness of NTM-LD caused by MAC is needed as patients with this disease experience substantial burden and unmet treatment needs. Areas covered: This review provides clinicians and regulatory and healthcare decision makers an overview of the clinical, economic, and humanistic burden of NTM-LD and the unmet treatment needs faced by patients and clinicians. The review focuses on NTM-LD caused by MAC. A summary of the 2020 NTM guidelines specifically for MAC-LD and an overview of novel treatment options, including amikacin liposome inhalation suspension (ALIS) as the first approved therapy for refractory MAC-LD, and investigational drugs in testing phase are provided. Expert opinion: Key advancements in NTM-LD management include recent updates to clinical practice guidelines, approval of ALIS for the treatment of refractory MAC-LD, and ongoing clinical trials of investigational treatments. Yet opportunities still exist to improve patient outcomes, including development of better screening tools, such as reliable and responsive biomarkers to help identify high-risk patients, and addressing unmet treatment needs.